Silo Pharma, Inc. (Nasdaq: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research,...
A first-of-its-kind review suggests that regular treatments are effective at reducing risk of relapse, though researchers say more study is needed. The...
The article Wonderland 2022 Review: MindBio Therapeutics was originally published on Microdose. With Wonderland 2022 still fresh in our rear-view mirrors,...
Months after Sens. Cory Booker (D-NJ) and Rand Paul (R-KY) introduced a bill that would expand access to Schedule I drugs for terminally ill patients,...
Cathie Wood has built her career on holding contrarian views and her Ark Invest firm has been known to go against the grain. As such, 2022’s...
Filament Health Corp. (OTCQB: FLHLF | NEO: FH) (FSE: 7QS), a clinical‐stage natural psychedelic drug development company, today announced an agreement...
MAPS Public Benefit Corporation (“MAPS PBC”), a private company dedicated to the development and commercialization of psychedelic medicines, announced...
The Covid-19 pandemic shifted the economy in many ways. Some industries and practices became nearly obsolete. Other industries have seen exponential growth....
The article Predicting Psychedelic Outcomes was originally published on Microdose. One of the hardest parts about taking psychedelics is entering the...
The article MAPS Completes Second Phase 3 MDMA Trial was originally published on Microdose. MAPS PBC Completes Second Phase 3 “MAPP2” Trial of...